-
Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report for the third quarter of 2024, highlighting overall revenues of RMB 30.912 billion (USD 4.33 billion) for the first three quarters, marking a 5.74% year-on-year (YOY) increase excluding COVID-19 related products. The company’s revenues for…
-
Shanghai Fosun Pharmaceutical Gets NMPA Clinical Clearance for Lymphoma Drug XS-04
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent pharmaceutical company based in China, has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its investigational drug XS-04 for the treatment of hematologic malignancies. XS-04, an innovative small molecule drug developed…
-
Shanghai Fosun Pharmaceutical’s SBK010 Stroke Treatment Accepted for NMPA Review
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that the National Medical Products Administration (NMPA) has accepted a market filing for its chemical drug SBK010 for review. SBK010, which is licensed from Chengdu Shibekang Biomedical Technology Co., Ltd, another…
-
Shanghai Fosun Pharmaceutical Partners with State-owned Firms to Boost ASEAN Drug Trade
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has entered into a strategic partnership with Zhongheng Group (SHA: 600252) and Nanning Industrial Investment Unified Investment Management Co., Ltd, both of which are controlled by state-owned investment companies. The financial specifics of the…
-
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
•
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute Co., Ltd, has entered into a strategic partnership with Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Gilead’s subsidiary Kite Pharma. The collaboration…
-
Fosun Pharma to Acquire Full Stake in Fosun Kite Biotechnology for USD 27 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has disclosed plans to acquire the remaining 50% stake in its joint venture, Fosun Kite Biotechnology Co., Ltd, from Gilead’s subsidiary Kite Pharma for USD 27 million. This transaction will see Fosun Pharma assume full ownership of Fosun Kite, with…
-
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has granted market approval for its product Daxxify (daxibotulinumtoxin, RT002). This type A botulinum toxin is now approved for the temporary improvement of moderate to severe eyebrow wrinkles in adults in…
-
Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has reported its financial results for the first half of 2024. The Chinese pharmaceutical giant recorded an operating revenue of RMB 20.463 billion, reflecting a 5.31% year-on-year increase,…
-
Fosun Pharma’s Privatization of Henlius Includes Cash and Share Offers, Aims for Full Equity Control
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and the Hong Kong Stock Exchange (HKG: 2196), has unveiled plans to privatize its subsidiary, Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696). In a cash transaction, Fosun Pharma intends to offer HKD 24.60 per share to…
-
Fosun Pharma’s West African Project Nears First-Phase Completion, Aims for 5 Billion Drug Units Annually
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) has announced the anticipated completion of the first phase of a significant project in Côte d’Ivoire, West Africa. Upon full completion, the project is set to produce 5 billion drug units per year and will feature a warehouse facility capable…
-
Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary of Gilead, have announced plans to bolster their joint venture, Fosun Kite Biotechnology Co., Ltd, through a capital increase. This will be achieved by proportionally converting their existing debt into equity, amounting to USD 28.5…
-
Shanghai Fosun Pharmaceutical Gets NMPA Green Light for FH-2001 and Serplulimab Combo Clinical Trial
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a prominent pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its co-developed FH-2001 in combination with HanSiZhuang (serplulimab, HLX10) for the treatment of advanced…
-
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696) private. According to a stock exchange announcement from the China-based firm, Fosun currently holds 323.7 million shares of Henlius, representing 59.56% of the company’s total shares.…
-
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of a 6.01% stake in its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), through bulk trading. The transaction raised INR 7.541 billion (USD 90 million) pre-tax, or approximately USD 211 million pre-tax. Following the completion of…
-
Fosun Pharma’s FCN-159 Receives Priority Review Status from NMPA for Pediatric Neurofibromatosis
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for the novel small-molecule drug candidate FCN-159, granting it priority review status. The filing seeks approval for the treatment of plexiform neurofibroma (PN)…
-
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
•
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) is planning to fully acquire its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696). This strategic move comes as Henlius, a Hong Kong-listed company, has suspended its shares from trading…
-
Shanghai Fosun Pharma’s FCN-159 File for Dendritic and Histiocytic Tumors Accepted by China’s NMPA
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has accepted its market approval filing for the novel small-molecule drug FCN-159 for review. The drug is being considered for the treatment of dendritic and histiocytic tumors, indications that have previously…
-
Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar drug HanDaYuan has received additional indication approvals from China’s National Medical Products Administration (NMPA). HanDaYuan, a biosimilar version of AbbVie’s Humira (adalimumab), an autoimmune disease therapy, is now approved to treat a wider range of…
-
Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in China, has announced that its subsidiary, Fosun Diagnostics (Shanghai) Co., Ltd, has entered into a strategic partnership with Jointown Medical Devices Group Co., Ltd. The collaboration aims to enhance product commercialization and strengthen the supply…
-
Shanghai Fosun Pharma’s FCN-159 Receives Priority Review for Pediatric Neurofibromatosis Treatment
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has achieved a significant milestone with its novel small-molecule chemical drug FCN-159, as indicated on the Center for Drug Evaluation’s (CDE) website. The drug has been granted priority review status for the treatment of plexiform neurofibroma (PN) in children aged…
-
Fosun Pharma Nods to Fosun Health Spin-Off; IPO Venue and Requirements Under Review
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company in China, has announced that its board of directors has given the green light to pre-planning activities for the spin-off of its subsidiary, Fosun Health. The company is currently in discussions regarding the potential initial public…
-
Insilico Medicine’s ISM8207 Enters Phase I Clinical Trial for Lymphoma and Solid Tumors
•
China’s generative artificial intelligence (AI)-driven biotech firm, Insilico Medicine, has announced the first patient dosing in a Phase I clinical study for ISM8207, a potential first-in-class drug candidate co-developed with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196). The open-label, multi-center Phase I study aims to evaluate the…
-
Fosun Pharmaceutical Advances Lasofocine Clinical Trials for Breast Cancer after NMPA Nod
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct two clinical studies for lasofociene. The first trial is a Phase I study in healthy subjects, while the second is a global multi-center Phase…
-
Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced the commencement of two Phase III clinical studies in collaboration with Japan’s Meiji Seika Pharma. These studies are focused on their co-developed anti-infective, Nacubactam (OP0595), which is being tested in combination…
-
Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has released its financial report for 2023, recording RMB 41.4 billion (USD 5.73 billion) in revenues, marking a -5.81% year-on-year (YOY) decrease. However, excluding the loss of COVID-19 product sales, the figure shows…
-
Intuitive Surgical’s Ion Robotic System Gains Regulatory Approval in China
•
Intuitive Surgical (NASDAQ: ISRG), a leading medical robotics firm based in the US, has announced that it has received regulatory approval in China for its Ion surgical robot system. Initially approved in the US in 2019, the Ion system is a robotic-assisted, catheter-based platform designed for minimally invasive biopsy procedures…
-
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish a RMB 5 billion (USD 695 million) fund in collaboration with seven other investors, with Shenzhen FOF expected to contribute 50% of the total funding. The initiative aims to enhance resource sharing and cooperation between…
-
Fosun Pharmaceutical Gets NMPA Green Light for Phase I Study of Fibrosis Drug HLX6018
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its drug candidate HLX6018. This investigational compound is a GARP/TGF-β1 compound…
-
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its universal NK cell therapy, GCK-01. This Category 1 innovative therapeutic…
-
Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate XS-02 in patients with advanced solid tumors. XS-02 is a…
-
Shanghai Fosun Pharma’s GCK-01 CAR-NK Cell Therapy Gets Tacit Clinical Approval from China’s CDE
•
The China Center for Drug Evaluation (CDE) website has indicated that Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), has received tacit approval for a Category 1 biologic preparation, GCK-01, to proceed with clinical trials. The therapeutic candidate is intended for the treatment of recurrent or refractory follicular…
-
Fosun Pharmaceutical Secures NMPA Approval for Phase II Study of FCN-338 and FCN-647 in Chronic Lymphocytic Leukemia
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its Bcl-2 inhibitor FCN-338 in combination with the BTK inhibitor FCN-647, targeting chronic lymphocytic leukemia/small lymphocytic lymphoma. FCN-338…
-
Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has accepted additional indication approval filings for its biosimilar HanDaYuan, which is modeled after AbbVie’s autoimmune therapy Humira (adalimumab). The company is seeking approval for HanDaYuan to treat polyarthritic juvenile idiopathic…
-
Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196，HKG: 2196), a Chinese pharmaceutical heavyweight, has entered into a strategic partnership with Nanning City in Guangxi province, China’s gateway to the ASEAN region. The collaboration aims to explore opportunities in biopharmaceuticals, intelligent manufacturing, finance and insurance, commerce, culture, tourism, and other sectors.…
-
Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for its pipeline drug candidate, FCN-338. This small-molecule Bcl-2 inhibitor will…
-
Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has received market approval from the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan) for its anti-PD-1 monoclonal antibody, HanSiZhuang (serplulimab). This approval allows the drug to be used in the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Henlius is collaborating with…
-
Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment
•
Fosun Pharmaceutical (Group) Co., Ltd. (HKG: 2196; SHA: 600196) has announced that its antibody-drug conjugate (ADC) HLX42 has received fast-track designation from the U.S. Food and Drug Administration (FDA). The drug is being co-developed with its subsidiary Shanghai Henlius Biotech Inc. (HKG: 2696) and Suzhou-based Medilink Therapeutics, specifically targeting advanced…
-
Shanghai Fosun to Exclusively Commercialize Generic Entresto in China
•
Nanjing F&S Pharmatech Co., Ltd has officially launched its generic version of Novartis’s heart failure therapy Entresto (sacubitril, valsartan) in China, with exclusive commercialization rights held by Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196). Entresto, a breakthrough treatment for chronic heart failure, was first approved in China in 2017…
-
Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial
•
Shanghai Fosun Pharmaceutical Co., Ltd (SHA: 600196, HKG: 2196) has received financial backing of JPY 500 million (USD 3.3 million) from the Japan-based Global Health Innovative Technology (GHIT) Fund for a Phase III trial of a triple artemisinin combination drug aimed at treating malaria. Fosun Pharmaceutical is developing a fixed-dose…
-
Fosun Pharmaceutical and Insightec Form JV to Bring MRgFUS Brain Therapy to China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to establish a joint venture (JV) with Israeli company Insightec. The new JV will concentrate on the commercial development and clinical application of a magnetic resonance guided focused ultrasound (MRgFUS) brain therapy system in China, targeting patients with Parkinson’s…
-
Shanghai Henlius Biotech Submits Another Application for Serplulimab in China
•
Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new market filing for its anti-programmed death-1 (PD-1) drug, HanSiZhuang (serplulimab), seeking approval for use in combination with chemotherapy for first-line non-squamous non-small cell lung cancer (nsqNSCLC). The filing, accepted for review by the National Medical Products Administration (NMPA), marks the…
-
Sisram Medical’s Profhilo Accepted for Review by China’s NMPA
•
Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196), has announced that its licensed injection filler product, Prohiro, has had its market filing accepted for review by China’s National Medical Products Administration (NMPA). Profhilo, an injectable sodium hyaluronate solution, is recognized as one of…
-
Fosun Pharma to Establish Greater Bay Area HQ in Shenzhen’s Pingshan District
•
Local media outlets report that Fosun International’s chairman, Guo Guangchang, announced at a business event in Shenzhen the establishment of a Greater Bay Area (GBA) headquarters for Fosun Pharma (HKG: 2196, SHA: 600196) in the Pingshan district of Shenzhen. This new site will serve as Fosun Pharma’s second global headquarters,…
-
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for HLX42, an antibody drug conjugate (ADC) co-developed with Shanghai Henlius Biotech Inc. (HKG: 2696) and Suzhou-based Medilink Therapeutics. The study targets advanced/metastatic…
-
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
•
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National Medical Products Administration (NMPA) has accepted for review its market approval filing for FCN-437c. The small molecule drug candidate is under development for the treatment of hormone receptor (HR) positive and human epidermal growth factor…
-
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
•
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma USA, is partnering with Treehill Partners, a US-based financial and deal-making advisory firm specializing in the healthcare sector. The collaboration aims to establish a jointly operated investment vehicle targeting individual clinical-stage assets. Targeting High-Potential Clinical-Stage…
-
Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for its VT-101 from both the National Medical Products Administration (NMPA) in China and the US Food and Drug Administration (FDA). VT-101 is a next-generation recombinant oncolytic adenovirus product that features a triple-targeted tumor regulation mechanism,…
-
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
•
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a platform for multiple companies to announce their strategic partnerships in China. Among the notable participants are Danaher (NYSE: DHR), Boehringer-Ingelheim (BI), Merck Sharp & Dohme (MSD, NYSE: MRK), Johnson & Johnson (J&J, NYSE: JNJ), BeiGene…
-
Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based medical device company Insightec Ltd, a leader in magnetic resonance (MR)-guided Focused Ultrasound equipment. This partnership aims to apply Insightec’s advanced Focused Ultrasound brain therapy technology for the treatment of idiopathic tremors and Parkinson’s disease…
-
Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE
•
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and US-based Intuitive Surgical Inc., has announced the official launch of the Da Vinci Xi surgical robot at the 6th China International Import Expo (CIIE) in Shanghai. The Da Vinci Xi…
-
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval from the National Medical Products Administration (NMPA) in China to conduct separate clinical studies for HLX42 and HLX43. These two pipeline candidates are antibody drug conjugates (ADCs) co-developed by subsidiary Shanghai Henlius Biotech Inc., (HKG:…
-
Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase I clinical study for its investigational drug, XS-03. This study will focus on evaluating the drug’s efficacy in…
-
Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the receipt of two Good Manufacturing Practice (GMP) certificates from Brazil’s National Health Surveillance Agency (ANVISA). This certification confirms that Henlius’ biologics manufacturing plant located in the Xuhui district of…
-
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9 million (USD 34 million) in the acquisition of 97.22 million new shares of UnitedHealthcare, securing a 14% stake in the insurance firm. This strategic investment aims to diversify Fosun’s portfolio and enhance its presence in…
-
Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has announced the commencement of a Phase III clinical study for its drug ET-26 (methoxyethyl etomidate). This marks a significant milestone in the development of new anesthetic solutions, with ET-26 being evaluated as an induction therapy…
-
Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses of two of its key products. The company’s Programmed-death 1 (PD-1) inhibitor, HaiSiZhuang (serplulimab), has been approved for a new indication in the treatment of first-line PD-L1 positive unresectable locally advanced/recurrent or metastatic esophageal squamous…
